JP2024534410A5 - - Google Patents

Info

Publication number
JP2024534410A5
JP2024534410A5 JP2024516730A JP2024516730A JP2024534410A5 JP 2024534410 A5 JP2024534410 A5 JP 2024534410A5 JP 2024516730 A JP2024516730 A JP 2024516730A JP 2024516730 A JP2024516730 A JP 2024516730A JP 2024534410 A5 JP2024534410 A5 JP 2024534410A5
Authority
JP
Japan
Prior art keywords
transcription factor
vector
factor according
sequence
tad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/058691 external-priority patent/WO2023042104A1/en
Publication of JP2024534410A publication Critical patent/JP2024534410A/ja
Publication of JP2024534410A5 publication Critical patent/JP2024534410A5/ja
Pending legal-status Critical Current

Links

JP2024516730A 2021-09-16 2022-09-15 新規転写因子 Pending JP2024534410A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245084P 2021-09-16 2021-09-16
US63/245,084 2021-09-16
PCT/IB2022/058691 WO2023042104A1 (en) 2021-09-16 2022-09-15 Novel transcription factors

Publications (2)

Publication Number Publication Date
JP2024534410A JP2024534410A (ja) 2024-09-20
JP2024534410A5 true JP2024534410A5 (https=) 2025-09-24

Family

ID=84330751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516730A Pending JP2024534410A (ja) 2021-09-16 2022-09-15 新規転写因子

Country Status (5)

Country Link
US (1) US20240398985A1 (https=)
EP (1) EP4402265A1 (https=)
JP (1) JP2024534410A (https=)
CN (1) CN117980484A (https=)
WO (1) WO2023042104A1 (https=)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
ES2341926T3 (es) 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
US9632244B2 (en) 2014-07-28 2017-04-25 Panduit Corp. Multimode optical fiber and methods of manufacturing thereof
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
US10059940B2 (en) 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
WO2019000093A1 (en) * 2017-06-29 2019-01-03 UNIVERSITé LAVAL PLATINUM TALE AND USE THEREOF TO INCREASE THE EXPRESSION OF FRATAXIN
WO2019094253A1 (en) 2017-11-08 2019-05-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
JP7624728B2 (ja) * 2019-02-25 2025-01-31 ユニバーシティ オブ マサチューセッツ Dna結合ドメイントランスアクチベーター及びその使用
PL3976798T3 (pl) * 2019-05-29 2026-04-07 Encoded Therapeutics, Inc. Kompozycje i sposoby selektywnej regulacji genów

Similar Documents

Publication Publication Date Title
JP2021505133A5 (https=)
JP2023518541A5 (https=)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2021512649A5 (https=)
JP2022535749A5 (https=)
US10016514B2 (en) Polynucleotides, vectors and methods for insertion and expression of transgenes
JP2024099770A5 (https=)
JP2022523679A5 (https=)
JP2022521432A5 (https=)
JP2023535620A5 (https=)
JP2025120285A5 (https=)
JP2023537980A5 (https=)
JP7618581B2 (ja) 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用
WO2022165362A2 (en) Epigenetic gene regulation to treat neurological diseases and pain
JP2023535025A5 (https=)
JP2022529500A5 (https=)
JP2024532262A5 (https=)
JP2024534410A5 (https=)
JP2021533742A (ja) 新規転写アクチベーター
AU2019249374B2 (en) Compositions and methods for the treatment of dominantly-inherited catecholaminergic polymorphic ventricular tachycardia
CA3218631A1 (en) Vector system
US20240398985A1 (en) Novel transcription factors
WO2025076201A1 (en) Human-targeted zinc finger protein to treat angelman syndrome
JP2020533313A5 (https=)
Скопенкова et al. Muscle-Specific Promoters for Gene Therapy